SRC-3 has a role in cancer other than as a nuclear receptor coactivator

International Journal of Biological Sciences

Volumn 7, Issue 5, 2011, Pages 664-672

  Ma, Gang ^a   Ren, Yu ^a   Wang, Ke ^a   He, Jianjun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Inva sion and metastasis; Mice model; Steroid receptor coactivator 3; Tumorigenesis

Indexed keywords

MUS; MUS MUSCULUS;

EID: 79960128492     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.7.664     Document Type: Review

References (81)

1. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997; 277: 965-8.
2. Liao L, Kuang SQ, Yuan Y, Gonzalez SM, O'Malley BW, Xu J. Molecular structure and biological function of the can-cer-amplified nuclear receptor coactivator SRC-3/AIB1. J Ster-oid Biochem Mol Biol. 2002; 83: 3-14.
3. Amazit L, Pasini L, Szafran AT, et al. Regulation of SRC-3 in-tercompartmental dynamics by estrogen receptor and phos-phorylation. Mol Cell Biol. 2007; 27: 6913-32.
4. Louie MC, Zou JX, Rabinovich A, Chen HW. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol. 2004; 24: 5157-71.
5. Yan J, Yu CT, Ozen M, Ittmann M, Tsai SY, Tsai MJ. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res. 2006; 66: 11039-46.
6. Werbajh S, Nojek I, Lanz R, Costas MA. RAC-3 is a NF-kappa B coactivator. FEBS Lett. 2000; 485: 195-9.
7. Arimura A, vn PM, Schroder AJ, Rothman PB. The transcrip-tional co-activator p/CIP (NCoA-3) is up-regulated by STAT6 and serves as a positive regulator of transcriptional activation by STAT6. J Biol Chem. 2004; 279: 31105-12.
8. Qin L, Liao L, Redmond A, et al. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol. 2008; 28: 5937-50.
9. Yu C, York B, Wang S, Feng Q, Xu J, O'Malley BW. An essential function of the SRC-3 coactivator in suppression of cytokine mRNA translation and inflammatory response. Mol Cell. 2007; 25: 765-78.
10. Bautista S, Valles H, Walker RL, et al. In breast cancer, ampli-fication of the steroid receptor coactivator gene AIB1 is corre-lated with estrogen and progesterone receptor positivity. Clin Cancer Res. 1998; 4: 2925-9.
11. Glaeser M, Floetotto T, Hanstein B, Beckmann MW, Niedera-cher D. Gene amplification and expression of the steroid re-ceptor coactivator SRC3 (AIB1) in sporadic breast and endo-metrial carcinomas. Horm Metab Res. 2001; 33: 121-6.
12. Iwase H, Omoto Y, Toyama T, et al. Clinical significance of AIB1 expression in human breast cancer. Breast Cancer Res Treat. 2003; 80: 339-45.
13. Kirkegaard T, McGlynn LM, Campbell FM, et al. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res. 2007; 13: 1405-11.
14. Bouras T, Southey MC, Venter DJ. Overexpression of the ster-oid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and posi-tivity for p53 and HER2/neu. Cancer Res. 2001; 61: 903-7.
15. Zhao C, Yasui K, Lee CJ, et al. Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer. 2003; 98: 18-23.
16. List HJ, Reiter R, Singh B, Wellstein A, Riegel AT. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat. 2001; 68: 21-8.
17. Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer CF. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a car-cinoma-specific co-activator. Breast Cancer Res Treat. 2003; 78: 193-204.
18. Thorat MA, Turbin D, Morimiya A, et al. Amplified in breast cancer 1 expression in breast cancer. Histopathology. 2008; 53: 634-41.
19. Alkner S, Bendahl PO, Grabau D, et al. AIB1 is a predictive factor for tamoxifen response in premenopausal women. Ann Oncol. 2010; 21: 238-44.
20. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003; 95: 353-61.
21. Harigopal M, Heymann J, Ghosh S, Anagnostou V, Camp RL, Rimm DL. Estrogen receptor co-activator (AIB1) protein ex-pression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome. Breast Cancer Res Treat. 2009; 115: 77-85.
22. Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer. 2001; 85: 1928-36.
23. Zhou HJ, Yan J, Luo W, et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 2005; 65: 7976-83.
24. Tanner MM, Grenman S, Koul A, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Can-cer Res. 2000; 6: 1833-9.
25. Yoshida H, Liu J, Samuel S, Cheng W, Rosen D, Naora H. Ster-oid receptor coactivator-3, a homolog of Taiman that controls cell migration in the Drosophila ovary, regulates migration of human ovarian cancer cells. Mol Cell Endocrinol. 2005; 245: 77-85.
26. Sakaguchi H, Fujimoto J, Sun WS, Tamaya T. Clinical implica-tions of steroid receptor coactivator (SRC)-3 in uterine endo-metrial cancers. J Steroid Biochem Mol Biol. 2007; 104: 237-40.
27. Balmer NN, Richer JK, Spoelstra NS, Torkko KC, Lyle PL, Singh M. Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: Correlation with clini-copathologic parameters and biomarkers. Mod Pathol. 2006; 19: 1593-605.
28. Fujita Y, Sakakura C, Shimomura K, et al. Chromosome arm 20q gains and other genomic alterations in esophageal squa-mous cell carcinoma, as analyzed by comparative genomic hy-bridization and fluorescence in situ hybridization. Hepatogas-troenterology. 2003; 50: 1857-63.
29. Xu FP, Xie D, Wen JM, et al. SRC-3/AIB1 protein and gene amplification levels in human esophageal squamous cell car-cinomas. Cancer Lett. 2007; 245: 69-74.
30. He LR, Liu MZ, Li BK, et al. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 2009; 100: 1591-6.
31. Xie D, Sham JS, Zeng WF, et al. Correlation of AIB1 overex-pression with advanced clinical stage of human colorectal car-cinoma. Hum Pathol. 2005; 36: 777-83.
32. Lassmann S, Weis R, Makowiec F, et al. Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med. 2007; 85: 293-304.
33. Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou AG, Kalofonos H. Estrogen receptor al-pha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance. Int J Colorectal Dis. 2009; 24: 613-22.
34. Wang Y, Wu MC, Sham JS, Zhang W, Wu WQ, Guan XY. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer. 2002; 95: 2346-52.
35. Xu Y, Chen Q, Li W, et al. Overexpression of transcriptional coactivator AIB1 promotes hepatocellular carcinoma progres-sion by enhancing cell proliferation and invasiveness. Onco-gene. 2010; 29: 3386-97.
36. Henke RT, Haddad BR, Kim SE, et al. Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin Cancer Res. 2004; 10: 6134-42.
37. Sakakura C, Hagiwara A, Yasuoka R, et al. Amplification and over-expression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers. Int J Cancer. 2000; 89: 217-23.
38. Luo JH, Xie D, Liu MZ, et al. Protein expression and amplifica-tion of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival. Int J Cancer. 2008; 122: 2554-61.
39. Liu MZ, Xie D, Mai SJ, et al. Overexpression of AIB1 in naso-pharyngeal carcinomas correlates closely with advanced tumor stage. Am J Clin Pathol. 2008; 129: 728-34.
40. He LR, Zhao HY, Li BK, et al. Overexpression of AIB1 nega-tively affects survival of surgically resected non-small-cell lung cancer patients. Ann Oncol. 2010; 21: 1675-81.
41. Cai D, Shames DS, Raso MG, et al. Steroid receptor coactiva-tor-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res. 2010; 70: 6477-85.
42. Wang H, Zhang D, Wu W, et al. Overexpression and gen-der-specific differences of SRC-3 (SRC-3/AIB1) immunoreac-tivity in human non-small cell lung cancer: an in vivo study. J Histochem Cytochem. 2010; 58: 1121-7.
43. Carroll RS, Brown M, Zhang J, DiRenzo J, De Mora J F, Black PM. Expression of a subset of steroid receptor cofactors is asso-ciated with progesterone receptor expression in meningiomas. Clin Cancer Res. 2000; 6: 3570-5.
44. Kuang SQ, Liao L, Zhang H, Lee AV, O'Malley BW, Xu J. AIB1/SRC-3 deficiency affects insulin-like growth factor I sig-naling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res. 2004; 64: 1875-85.
45. Kuang SQ, Liao L, Wang S, Medina D, O'Malley BW, Xu J. Mice lacking the amplified in breast cancer 1/steroid receptor coac-tivator-3 are resistant to chemical carcinogen-induced mam-mary tumorigenesis. Cancer Res. 2005; 65: 7993-8002.
46. Fereshteh MP, Tilli MT, Kim SE, et al. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumor-igenesis in mice. Cancer Res. 2008; 68: 3697-706.
47. Ying H, Willingham MC, Cheng SY. The steroid receptor coac-tivator-3 is a tumor promoter in a mouse model of thyroid cancer. Oncogene. 2008; 27: 823-30.
48. Torres-Arzayus MI, de Mora J F, Yuan J, et al. High tumor incidence and activation of the PI3K/AKT pathway in trans-genic mice define AIB1 as an oncogene. Cancer Cell. 2004; 6: 263-74.
49. Torres-Arzayus MI, Zhao J, Bronson R, Brown M. Estro-gen-dependent and estrogen-independent mechanisms con-tribute to AIB1-mediated tumor formation. Cancer Res. 2010; 70: 4102-11.
50. Park MT, Lee SJ. Cell cycle and cancer. J Biochem Mol Biol. 2003; 36: 60-5.
51. Louie MC, Revenko AS, Zou JX, Yao J, Chen HW. Direct control of cell cycle gene expression by proto-oncogene product ACTR, and its autoregulation underlies its transforming activity. Mol Cell Biol. 2006; 26: 3810-23.
52. Avivar A, Garcia-Macias MC, Ascaso E, Herrera G, O'Connor JE, de Mora JF. Moderate overexpression of AIB1 triggers pre-neoplastic changes in mammary epithelium. FEBS Lett. 2006; 580: 5222-6.
53. Mussi P, Yu C, O'Malley BW, Xu J. Stimulation of steroid re-ceptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Mol Endocrinol. 2006; 20: 3105-19.
54. Hsia EY, Kalashnikova EV, Revenko AS, Zou JX, Borowsky AD, Chen HW. Deregulated E2F and the AAA+ coregulator ANCCA drive proto-oncogene ACTR/AIB1 overexpression in breast cancer. Mol Cancer Res. 2010; 8: 183-93.
55. Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer. 2005; 92: 2097-101.
56. Wang Z, Rose DW, Hermanson O, et al. Regulation of somatic growth by the p160 coactivator p/CIP. Proc Natl Acad Sci U S A. 2000; 97: 13549-54.
57. Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, O'Malley BW. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci U S A. 2000; 97: 6379-84.
58. Zhou G, Hashimoto Y, Kwak I, Tsai SY, Tsai MJ. Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol. 2003; 23: 7742-55.
59. Oh A, List HJ, Reiter R, et al. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res. 2004; 64: 8299-308.
60. Rajah R, Bhala A, Nunn SE, Peehl DM, Cohen P. 7S nerve growth factor is an insulin-like growth factor-binding protein protease. Endocrinology. 1996; 137: 2676-82.
61. York B, Yu C, Sagen JV, et al. Reprogramming the posttransla-tional code of SRC-3 confers a switch in mammalian systems biology. Proc Natl Acad Sci U S A. 2010; 107: 11122-7.
62. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366: 2-16.
63. Lahusen T, Fereshteh M, Oh A, Wellstein A, Riegel AT. Epi-dermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, ampli-fied in breast cancer 1. Cancer Res. 2007; 67: 7256-65.
64. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000; 21: 485-95.
65. Colo GP, Rubio MF, Nojek IM, et al. The p160 nuclear receptor co-activator RAC3 exerts an anti-apoptotic role through a cyto-plasmatic action. Oncogene. 2008; 27: 2430-44.
66. Colo GP, Rosato RR, Grant S, Costas MA. RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis. FEBS Lett. 2007; 581: 5075-81.
67. Sheikh MS, Huang Y. Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle. 2003; 2: 550-2.
68. Pajak B, Orzechowski A. [FLIP--an enemy which might lose the battle against the specific inhibitors of translation]. Postepy Hig Med Dosw (Online). 2005; 59: 140-9.
69. Wu RC, Qin J, Hashimoto Y, et al. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase. Mol Cell Biol. 2002; 22: 3549-61.
70. Li R, Chen Y, Shu WX, Chen Z, Ke WJ. Involvement of SRC-3 in deguelin-induced apoptosis in Jurkat cells. Int J Hematol. 2009; 89: 628-35.
71. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene. 2003; 22: 8983-98.
72. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005; 9: 59-71.
73. Vandermoere F, El YI, Adriaenssens E, Lemoine J, Honder-marck H. The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells. Oncogene. 2005; 24: 5482-91.
74. Horiguchi K, Arai S, Nishihara T, Nishikawa J. AIB1 promotes DNA replication by JNK repression and AKT activation during cellular stress. J Biochem. 2006; 140: 409-19.
75. Li R, Chen Y, Zeng LL, et al. Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inacti-vation of Akt pathway in K562 leukemia cells. Toxicology. 2009; 262: 98-105.
76. Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol. 2008; 214: 283-93.
77. Yan J, Erdem H, Li R, et al. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhe-sion turnover and matrix metalloproteinase expression. Cancer Res. 2008; 68: 5460-8.
78. Li LB, Louie MC, Chen HW, Zou JX. Proto-oncogene ACTR/AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression. Cancer Lett. 2008; 261: 64-73.
79. Chung AC, Zhou S, Liao L, Tien JC, Greenberg NM, Xu J. Ge-netic ablation of the amplified-in-breast cancer 1 inhibits spon-taneous prostate cancer progression in mice. Cancer Res. 2007; 67: 5965-75.
80. Long W, Yi P, Amazit L, et al. SRC-3Delta4 mediates the inter-action of EGFR with FAK to promote cell migration. Mol Cell. 2010; 37: 321-32.
81. Coste A, Antal MC, Chan S, et al. Absence of the steroid recep-tor coactivator-3 induces B-cell lymphoma. EMBO J. 2006; 25: 2453-64.